28 research outputs found
Ação do extrato de própolis sobre a fermentação in vitro de diferentes alimentos pela técnica de produção de gases
Relation between oral health and socioeconomic variables among schoolchildren aged 12 in the City of Manaus - AM
Consumo e digestibilidades dos nutrientes em bovinos recebendo dietas contendo silagens de milho e sorgo, com e sem inoculante microbiano
Religious first- teachers second': Catholic elementary schooling in nineteenth-century South Australia
We studied if the clinical pharmacokinetics and drug-drug interactions (DDIs) of the sulfonylurea-derivative glibenclamide can be simulated via a physiologically-based pharmacokinetic modeling approach. To this end, a glibenclamide PBPK-model was build in Simcyp using in vitro physicochemical and biotransformation data of the drug, and was subsequently optimized using plasma disappearance data observed after i.v. administration. The model was validated against data observed after glibenclamide oral dosing, including DDIs. We found that glibenclamide pharmacokinetics could be adequately modeled if next to CYP metabolism an active hepatic uptake process was assumed. This hepatic uptake process was subsequently included in the model in a non-mechanistic manner. After an oral dose of 0.875 mg predicted Cmax and AUC were 39.7 (95% CI:37.0-42.7)ng/mL and 108 (95% CI: 96.9-120)ng/mLh, respectively, which is in line with observed values of 43.6 (95% CI: 37.7-49.5)ng/mL and 133 (95% CI: 107-159)ng/mLh. For a 1.75 mg oral dose, the predicted and observed values were 82.5 (95% CI:76.6-88.9)ng/mL vs 91.1 (95% CI: 67.9-115.9) for Cmax and 224 (95% CI: 202-248) vs 324 (95% CI: 197-451)ng/mLh for AUC, respectively. The model correctly predicted a decrease in exposure after rifampicin pre-treatment. An increase in glibenclamide exposure after clarithromycin co-treatment was predicted, but the magnitude of the effect was underestimated because part of this DDI is the result of an interaction at the transporter level. Finally, the effects of glibenclamide and fluconazol co-administration were simulated. Our simulations indicated that co-administration of this potent CYP450 inhibitor will profoundly increase glibenclamide exposure, which is in line with clinical observations linking the glibenclamide-fluconazol combination to an increased risk of hypoglycemia. In conclusion, glibenclamide pharmacokinetics and its CYP-mediated DDIs can be simulated via PBPK-modeling. In addition, our data underline the relevance of modeling transporters on a full mechanistic level to further improve pharmacokinetic and DDI predictions of this sulfonylurea-derivative
Interaction of fluvastatin with the liver-specific Na(+)-dependent taurocholate cotransporting polypeptide (NTCP)
Contains fulltext :
91944.pdf (publisher's version ) (Closed access
Dawn maps the surface composition of Vesta
By 7-October-2011, the Dawn mission will have
completed Survey orbit and commenced high altitude
mapping of 4Vesta. We present a preliminary
analysis of data acquired by Dawn’s Framing Camera
(FC) and the Visual and InfraRed Spectrometer (VIR)
to map mineralogy and surface temperature, and to
detect and quantify surficial OH. The radiometric
calibration of VIR and FC is described. Background
counting data acquired by GRaND are used to
determine elemental detection limits from
measurements at low altitude, which will commence
in November. Geochemical models used in the
interpretation of the data are described. Thermal
properties, mineral-, and geochemical-data are
combined to provide constraints on Vesta’s
formation and thermal evolution, the delivery of
exogenic materials, space weathering processes, and
the origin of the howardite, eucrite, and diogenite
(HED) meteorites